Medtronic Presents Durable Endeavor DES Results At ESC Meeting
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial
You may also be interested in...
Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S
Boston Scientific Counters J&J In “Perception Battle” With New Taxus Data
Boston Scientific expects new clinical trial data presented at the Paris Course on Revascularization (PCR) May 24 to help reverse an ongoing shift of the drug-eluting stent market toward Johnson & Johnson/Cordis
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.